Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* YANCOPOULOS GEORGE	2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS, INC. [ REGN ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) President and CSO
(Last) (First) (Middle) 777 OLD SAW MILL RIVER ROAD	3. Date of Earliest Transaction (MM/DD/YYYY) 12/11/2019
(Street) TARRYTOWN, NY 10591 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/18/2019		G	V	325986	A	$0.00	325986	D
Common Stock	12/12/2019		M⁽¹⁾		95295	A	$21.25	421281	D
Common Stock	12/12/2019		F⁽¹⁾		49405	D	$377.16	371876	D
Common Stock	12/12/2019		M⁽¹⁾		150000	A	$21.25	521876	D
Common Stock	12/12/2019		F⁽¹⁾		77767	D	$377.16	444109	D
Common Stock	8/5/2019		G	V	75036	D	$0.00	0	I	by 2017 GRAT
Common Stock	2/19/2019		G	V	150722	D	$0.00	249278	I	by 2018 GRAT
Common Stock	6/13/2019		G	V	500000	A	$0.00	500000	I	by 2019 GRAT
Common Stock	2/19/2019		G	V	150722	A	$0.00	753316	I	by Trust
Common Stock	6/13/2019		G	V	500000	D	$0.00	253316	I	by Trust
Common Stock	8/5/2019		G	V	75036	A	$0.00	328352	I	by Trust
Common Stock	11/14/2019		G	V	2366	D	$0.00	325989	I	by Trust
Common Stock	11/18/2019		G	V	325986	D	$0.00	0	I	by Trust
Common Stock								5791	I	By 401(k) Plan

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Stock	⁽²⁾	11/18/2019		G	V	23367		⁽³⁾	⁽³⁾	Common Stock	23367	$0.00	23367	D
Class A Stock	⁽²⁾	11/18/2019		G	V		23367	⁽³⁾	⁽³⁾	Common Stock	23367	$0.00	0	I	By Trust
Class A Stock	⁽²⁾							⁽³⁾	⁽³⁾	Common Stock	5383		5383	I	By Son ⁽⁴⁾
Class A Stock	⁽²⁾							⁽³⁾	⁽³⁾	Common Stock	14000		14000	I	By Daughter ⁽⁴⁾
Non-Qualified Stock Option (right to buy)	$21.25	12/12/2019		M ⁽¹⁾			95295	⁽⁵⁾	12/18/2019	Common Stock	95295	$0.00	150000	D
Non-Qualified Stock Option (right to buy)	$21.25	12/12/2019		M ⁽¹⁾			150000	⁽⁶⁾	12/18/2019	Common Stock	150000	$0.00	0	D
Non-Qualified Stock Option (right to buy)	$372.46	12/11/2019		A		81278		⁽⁷⁾	12/11/2029	Common Stock	81278	$0.00	81278	D
Performance Stock Units	⁽⁸⁾	12/11/2019		A		25155		⁽⁸⁾	⁽⁸⁾	Common Stock	25155	$0.00	25155	D

Explanation of Responses:
(1)	Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
(2)	Class A Stock of Regeneron Pharmaceuticals, Inc. ("Regeneron") converts to Common Stock of Regeneron on a one-to-one basis upon certain events or upon election of the shareholder.
(3)	These shares of Class A Stock are presently convertible and such conversion feature does not expire.
(4)	These shares of Class A Stock are held in custody for the benefit of the reporting person's child.
(5)	The stock option award (combined incentive stock option and non-qualified stock option) vested in four equal annual installments, commencing one year after the date of grant.
(6)	The option became exercisable on December 31, 2012, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2012.
(7)	The stock option award vests in four equal annual installments, commencing one year after the date of grant.
(8)	Each performance-based restricted stock unit ("PSU") represents the contingent right to receive one share of the issuer's common stock at vesting. The amount reported reflects the maximum number of PSUs that may vest based upon the achievement of certain performance metrics related to total shareholder return over four-year and/or five-year performance periods ending on December 11, 2023 and December 11, 2024, respectively. Between 50% and 225% of the target number of PSUs (i.e., between 50% and 225% of 11,180 PSUs) may vest upon achievement of predetermined total shareholder return percentages derived from compound annual growth rates of 5% to 15% for the applicable performance period. If none of the performance metrics are achieved at the conclusion of the performance periods, the award expires.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
YANCOPOULOS GEORGE 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591	X		President and CSO